Norges Bank’s Bicara Therapeutics BCAX Stock Holding History

Norges Bank’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,889	Closed	-$722K	–	1500
2025 Q4	$722K	Buy	+42,889	New	+$732K	﹤0.01%	1539
2025 Q3	–	Sell	-42,889	Closed	-$398K	–	1671
2025 Q2	$398K	Hold	42,889	–	–	﹤0.01%	1646
2025 Q1	$559K	Sell	42,889 -27,111	-39%	-$360K	﹤0.01%	1681
2024 Q4	$1.22M	Hold	70,000	–	–	﹤0.01%	1742
2024 Q3	$1.78M	Buy	+70,000	New	+$1.79M	﹤0.01%	1669

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Norges Bank's BCAX Position: Q1 2026 in Review

Norges Bank sold out of Bicara Therapeutics (BCAX) in Q1 2026, closing a stake of 42,889 shares — an estimated $722K sold.

Norges Bank first reported a position in BCAX in Q3 2024 and held it in 5 quarters. The position peaked at $1.78M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

Norges Bank reported no remaining Bicara Therapeutics position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 42,889 Bicara Therapeutics shares in Q1 2026, an estimated $722K.
Norges Bank first reported a position in Bicara Therapeutics in Q3 2024 and held it in 5 quarters.
Norges Bank's Bicara Therapeutics position peaked at $1.78M in Q3 2024.
146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.